Medical Condition News

RSS

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Complementary and alternative health practices show promise for management of pain

A variety of complementary and alternative health practices —including meditation and relaxation techniques, manual therapies such as massage and spinal manipulation, meditative exercise forms such as yoga, Tai Chi, and ancient health practices such as acupuncture—show promise for contributing to the management of pain according to research presented at the Annual Scientific Meeting of the American Pain Society, www.ampainsoc.org.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

A team of scientists from Genome Institute of Singapore (GIS) of the Agency for Science, Technology and Research (A*STAR) have shown how proteins involved in controlling genes work together to carry out their functions in stem cells and demonstrated for the very first time, how they can change interaction partners to make other types of cells.

20 May 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

Free, online tool to track exercise-induced asthma

Running into breathing problems when you exercise? You may have exercise-induced bronchoconstriction (EIB), commonly referred to as exercise-induced asthma. The American College of Allergy, Asthma and Immunology (ACAAI) has developed a free, easy-to-use online tool to track your symptoms: MyEIBJournal.org.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Tornier announces launch of Porous Coated Affiniti Stem for shoulder joint replacement surgery

Tornier Inc. the operating subsidiary of Tornier N.V., a leading global medical device company focused on serving extremities specialists who treat orthopedic conditions of the shoulder, elbow, wrist, hand, ankle and foot, today announced the introduction of the Porous Coated Affiniti Stem for shoulder joint replacement surgery.

20 May 2011

Study: Costs get in way of cancer patients refilling their prescriptions

About 10 percent of cancer patients aren't taking the oral medicines they need either because of the cost or they feel they are already taking too many other drugs, according to a study released by health-care consulting company Avalere Health late Wednesday.

20 May 2011

HealthGrades identifies major flaws in hospital ratings study

The findings of a journal article published in the May issue of the Archives of Surgery are fundamentally flawed and could undermine patients ability to find high quality hospital care, according to HealthGrades. The article, Evaluating Popular Media and Internet-Based Hospital Quality Ratings for Cancer Surgery, compared outcomes for gastrointestinal cancer patients who underwent surgery at hospitals on HealthGrades' "America's 50 Best Hospitals" and US News and World Report's "America's Best Hospitals" lists.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Breakthrough injectable gel for treating degeneration of the intervertebral disc

Chronic lower back pain is a major problem for society - behind only headaches as the most common neurological ailment - and is frequently caused by degeneration of the intervertebral disc.

From The University of Manchester 20 May 2011

CSL-Behring recombinant factor research presented

Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL).

19 May 2011

Medical food resolves metabolic syndrome and cardiovascular risk factors

Researchers at the University of Florida and Metagenics Inc. today announced that a program consisting of a breakthrough medical food combined with a low-glycemic, Mediterranean-style diet is almost twice as effective as one of the best diets alone for lowering risk factors for cardiovascular disease, the leading cause of death in the U.S.

19 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the DRug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device.

19 May 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Medical Condition News

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Complementary and alternative health practices show promise for management of pain

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Free, online tool to track exercise-induced asthma

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Tornier announces launch of Porous Coated Affiniti Stem for shoulder joint replacement surgery

Study: Costs get in way of cancer patients refilling their prescriptions

HealthGrades identifies major flaws in hospital ratings study

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Breakthrough injectable gel for treating degeneration of the intervertebral disc

CSL-Behring recombinant factor research presented

Medical food resolves metabolic syndrome and cardiovascular risk factors

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News